78176
document
Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity .
78177
Intervention_Pharmacological
Clobazam
78178
Intervention_Pharmacological
benzodiazepine , clobazam .
78179
Intervention_Control
placebo
78180
Intervention_Pharmacological
clobazam
78181
Intervention_Control
placebo
78182
Intervention_Pharmacological
Clobazam
78183
Outcome_Physical
seizures
78184
Outcome_Other
frequency and severity
78185
Participant_Condition
catamenial epilepsy
78186
Participant_Sample-size
14
78187
Participant_Sample-size
18